SCHEMBL24436730

SCHEMBL24436730

CCOC(=O)CCN(C)c1cccc(C(C)C)c1-n1c(=O)[nH]c(=O)c2cc(F)c(-c3c(N)cccc3F)nc21

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
KRAS P01116 19/20 0.42
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24436331 0.91 KRAS (0.43) KRAS
SCHEMBL22848283 0.87 LMNA (0.35) KRASLMNA
SCHEMBL29614823 0.80 KRAS (0.42) KRAS
SCHEMBL29614843 0.80 KRAS (0.43) KRAS
SCHEMBL22848359 0.79 KRAS (0.43) KRAS
SCHEMBL29614782 0.79 KRAS (0.43) KRAS
SCHEMBL22848173 0.72 KRAS (0.47) KRAS
SCHEMBL24436734 0.72 KRAS (0.40) KRAS
SCHEMBL24436453 0.71 KRAS (0.48) KRAS
SCHEMBL29614983 0.71 KRAS (0.48) KRAS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153741-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153741-A1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885LMNA 2941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.